ArticleJournal of experimental & clinical cancer research : CR2022

DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.

Ewa Cendrowicz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.